Source: Annual Congress 2007 - Novel issues in the treatment and control of asthma
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
I. Litvinova, S. Ovcharenko, V. Makolkin (Moscow, Russian Federation). Using cardioselective beta-blockers in patients with cardiovascular diseases and asthma. Eur Respir J 2007; 30: Suppl. 51, 562

Member's Comments

No comment yet.

Related content which might interest you: Using cardioselective beta-blockers in patients with cardiovascular diseases and COPD Source: Eur Respir J 2005; 26: Suppl. 49, 294s Year: 2005 Effectiveness and safety of concurrent beta-blockers and inhaled bronchodilators in COPD with cardiovascular comorbidities Source: Eur Respir Rev, 26 (145) 160123; 10.1183/16000617.0123-2016 Year: 2017 Clinical and inhaled drug profile of COPD patients with indication for beta-blockers who are on beta-blockers Source: Annual Congress 2013 –Asthma and COPD management: novel clinical findings Year: 2013 Is the coprescription of Beta-blockers and Beta2-agonists justified in patients with coexisting COPD and CHF? Source: Annual Congress 2009 - Beta-blockers may now be beneficial in asthma and COPD Year: 2009 Association of cardiovascular risk with inhaled long-acting anti-muscarinic antagonists in COPD patients with impaired renal function Source: International Congress 2018 – Cardiovascular morbidities in COPD Year: 2018 Concurrent use of long-acting bronchodilators in COPD and the risk of adverse cardiovascular events Source: Eur Respir J, 49 (5) 1602245; 10.1183/13993003.02245-2016 Year: 2017 Impact of inhaled corticosteroids in patients with cardiovascular disease Source: Eur Respir Monogr 2020; 88: 251-263 Year: 2020 Risk of myocardial infarction and cardiovascular death associated with inhaled corticosteroids in COPD Source: Eur Respir J 2010; 35: 1003-1021 Year: 2010 Efficacy of roflumilast with concomitant cardiovascular medication in patients with COPD Source: Annual Congress 2013 –Novel mechanisms for established drugs for asthma and COPD management Year: 2013 Risks of diabetes mellitus and hyperglycaemic adverse events in patients with COPD taking inhaled corticosteroids Source: Annual Congress 2011 - Airways disease comorbidities and general aspects Year: 2011 The risk of cardiovascular disease associated with asthma may be mediated by short-acting β2-agonists Source: Annual Congress 2008 - Epidemiology of asthma and allergy Year: 2008 The impact of preventive treatment with long-acting β2 adrenergics agonists and inhaled glucocorticoids in the morbility and mortality of 1.543 events of severe acute exacerbations of asthma Source: Annual Congress 2009 - Epidemiology of atopy and asthma Year: 2009 The risk of hyperkalemia in COPD and asthma patients Source: International Congress 2019 – Phenotypes and comorbidities of airway diseases Year: 2019 Risks of diabetes mellitus and hyperglycaemic adverse events in patients with asthma taking inhaled corticosteroids Source: Annual Congress 2011 - Asthma management and response Year: 2011 Coexisting cardiovascular diseases increase the risk of exacerbations in patients with COPD Source: Annual Congress 2011 - Respiratory epidemiology: comorbidity Year: 2011 Pharmacological treatment of self-reported cardiovascular comorbidity in COPD patients Source: Eur Respir J 2007; 30: Suppl. 51, 453s Year: 2007 Use of metoprolol succinate in patients with cardiovascular diseases associated with asthma or chronic obstructive pulmonary disease (COPD) Source: Eur Respir J 2006; 28: Suppl. 50, 502s Year: 2006 Carvedilol, bisoprolol, and metoprolol use in patients with coexistent heart failure and chronic obstructive pulmonary disease: A nationwide population-based study Source: International Congress 2015 – New data on established treatments for COPD Year: 2015 Coexistence of cardiovascular diseases in patients with COPD Source: Annual Congress 2010 - COPD: systemic inflammation and comorbidities Year: 2010 Concurrent use of long-acting bronchodilators in COPD and the risk of adverse cardiovascular events: A population-based study Source: International Congress 2016 – Pharmacological treatment of COPD: focus on LABA/LAMA combinations Year: 2016